Dr Robert Carlisle

robert carlisle

BSc, MSc, PhD Birm


Dr Robert Carlisle


Associate Professor in Biomedical Engineering

Academic Background

Dr Robert Carlisle is an Associate Professor in Biomedical Engineering and head of the Drug and Vaccine Delivery group.  After completing a BSc in Biochemistry, an MSc in Toxicology and a PhD in Gene Delivery at Birmingham University, he worked for 8 years within the Department of Clinical Pharmacology and the Department of Oncology at the University of Oxford. The majority of his work has been concerned with achieving systemic delivery of anti-cancer agents for the treatment of metastatic cancer. This has included the development and testing non-viral and viral gene delivery systems and liposomal agents for the delivery of conventional chemotherapeutics. Recently this work has developed with the application of ultrasound as an external stimulus to both enhance transfer of such therapeutics from the bloodstream into tumours and to trigger their activation and penetration once there. Research within the labs covers the full scope of therapeutic design, formulation and testing with emphasis on how the specificity and efficacy of delivery can be improved. 

Selected Publications

  • Grundy M, Coussios C, Carlisle R. Advances in systemic delivery of anti-cancer agents for the treatment of metastatic cancer. Expert Opin Drug Deliv 2016:1-15.
  • Weissmueller NT, Schiffter HA, Carlisle RC, et al. Needle-Free Dermal Delivery of a Diphtheria Toxin CRM197 Mutant on Potassium-Doped Hydroxyapatite Microparticles. Clin Vaccine Immunol 2015;22(5):586-92.
  • Mo S, Carlisle R, Laga R, et al. Increasing the density of nanomedicines improves their ultrasound-mediated delivery to tumours. J Control Release 2015.
  • Kwan JJ, Myers R, Coviello CM, et al. Ultrasound-Propelled Nanocups for Drug Delivery. Small 2015;11(39):5305-14.
  • Kwan JJ, Graham S, Myers R, et al. Ultrasound-induced inertial cavitation from gas-stabilizing nanoparticles. Phys Rev E Stat Nonlin Soft Matter Phys 2015;92(2):023019.
  • Al-Kadi OS, Chung DY, Carlisle RC, et al. Quantification of ultrasonic texture intra-heterogeneity via volumetric stochastic modeling for tissue characterization. Med Image Anal 2015;21(1):59-71.
  • Shah A, Graham S, Myers R, et al. Sonosensitive nanoliposomes releasable exclusively by sonovue-nucleated inertial cavitation. International society for therapeutic ultrasound 2014;Las vegas.
  • Graham SM, Carlisle R, Choi JJ, et al. Inertial cavitation to non-invasively trigger and monitor intratumoral release of drug from intravenously delivered liposomes. J Control Release 2014;178:101-7.
  • Choi JJ, Carlisle RC, Coviello C, et al. Non-invasive and real-time passive acoustic mapping of ultrasound-mediated drug delivery. Phys Med Biol 2014;59(17):4861-77.
  • Weissmueller N, Schiffter H, Carlisle R, et al. Diphtheria Toxin Mutant CRM197: Aluminum Adjuvantation Alters Secondary Structure and Thermal Unfolding Behavior
  • American Association of Pharmaceutical Scientists 2013;San Diego.
  • Stevenson M, Carlisle R, Davies B, et al. Development of a Positive-readout Mouse Model of siRNA Pharmacodynamics. Mol Ther Nucleic Acids 2013;2:e133.
  • Carlisle R, Coussios CC. Mechanical approaches to oncological drug delivery. Ther Deliv 2013;4(10):1213-5.
  • Carlisle R, Choi J, Bazan-Peregrino M, et al. Enhanced tumor uptake and penetration of virotherapy using polymer stealthing and focused ultrasound. J Natl Cancer Inst 2013;105(22):1701-10.
  • Bazan-Peregrino M, Sainson RC, Carlisle RC, et al. Combining virotherapy and angiotherapy for the treatment of breast cancer. Cancer Gene Ther 2013;20(8):461-8.
  • Bazan-Peregrino M, Rifai B, Carlisle RC, et al. Cavitation-enhanced delivery of a replicating oncolytic adenovirus to tumors using focused ultrasound. J Control Release 2013;169(1-2):40-7.
  • Carlisle, R., Seymour, L.W. & Coussios, C.C. Targeting of Liposomes via PSGL1 for Enhanced Tumor Accumulation. Pharm Res (2012).
  • S. Mo, C.-C. Coussios, L. Seymour, and R. Carlisle. “Ultrasound-enhanced drug delivery for cancer.” Expert Opinion on Drug Delivery 9(12): 15125-1538 (2012).
  • R., Carlisle, R., Tangney, M., Ulbrich, K. & Seymour, L.W. Polymer coatings for delivery of nucleic acid therapeutics. J Control Release 161, 537-553 (2012).
  • Chen, H.H., et al. Active adenoviral vascular penetration by targeted formation of heterocellular endothelial-epithelial syncytia. Mol Ther 19, 67-75 (2011).
  • Willemsen, R.A., et al. Multi-component polymeric system for tumour cell-specific gene delivery using a universal bungarotoxin linker. Pharm Res 27, 2274-2282 (2010).
  • Schenk, E., et al. Clinical adenoviral gene therapy for prostate cancer. Hum Gene Ther 21, 807-813 (2010).
  • de Vrij, J., et al. Adenovirus-derived vectors for prostate cancer gene therapy. Hum Gene Ther 21, 795-805 (2010).
  • Subr, V., et al. Coating of adenovirus type 5 with polymers containing quaternary amines prevents binding to blood components. J Control Release 135, 152-158 (2009).
  • Carlisle, R.C., et al. Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood 113, 1909-1918 (2009).
  • Bazan-Peregrino, M., et al. Comparison of molecular strategies for breast cancer virotherapy using oncolytic adenovirus. Hum Gene Ther 19, 873-886 (2008).
  • Bazan-Peregrino, M., Carlisle, R.C., Purdie, L. & Seymour, L.W. Factors influencing retention of adenovirus within tumours following direct intratumoural injection. Gene Ther 15, 688-694 (2008).
  • Carlisle, R.C., et al. Coating of adeno-associated virus with reactive polymers can ablate virus tropism, enable retargeting and provide resistance to neutralising antisera. J Gene Med 10, 400-411 (2008).
  • Carlisle, R.C., et al. Use of synthetic vectors for neutralising antibody resistant delivery of replicating adenovirus DNA. Gene Ther 13, 1579-1586 (2006).
  • Zhou, Q.H., Miller, D.L., Carlisle, R.C., Seymour, L.W. & Oupicky, D. Ultrasound-enhanced transfection activity of HPMA-stabilized DNA polyplexes with prolonged plasma circulation. J Control Release 106, 416-427 (2005).
  • Carlisle, R.C., et al. Polymer-coated polyethylenimine/DNA complexes designed for triggered activation by intracellular reduction. J Gene Med 6, 337-344 (2004).
  • Carlisle, R.C., et al. Adenovirus hexon protein enhances nuclear delivery and increases transgene expression of polyethylenimine/plasmid DNA vectors. Mol Ther 4, 473-483 (2001).
  • Ogris, M., Carlisle, R.C., Bettinger, T. & Seymour, L.W. Melittin enables efficient vesicular escape and enhanced nuclear access of nonviral gene delivery vectors. J Biol Chem 276, 47550-47555 (2001).
  • Bettinger, T., Carlisle, R.C., Read, M.L., Ogris, M. & Seymour, L.W. Peptide-mediated RNA delivery: a novel approach for enhanced transfection of primary and post-mitotic cells. Nucleic Acids Res 29, 3882-3891 (2001).
  • Oupicky, D., Carlisle, R.C. & Seymour, L.W. Triggered intracellular activation of disulfide crosslinked polyelectrolyte gene delivery complexes with extended systemic circulation in vivo. Gene Ther 8, 713-724 (2001).